Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of exenatide plus metformin vs. premixed human insulin aspart plus metformin on glycemic control and hypoglycemia in patients with inadequate control of type 2 diabetes on oral antidiabetic treatment.

Next Previous
X
Search
Trial Profile

Effect of exenatide plus metformin vs. premixed human insulin aspart plus metformin on glycemic control and hypoglycemia in patients with inadequate control of type 2 diabetes on oral antidiabetic treatment.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary) ; Insulin aspart/insulin protamine aspart
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amylin Pharmaceuticals

    • Most Recent Events

    • 29 Jun 2010 Results of the metformin only pretreatment arm were presented at the 70th Scientific Sessions of the American Diabetes Association.
    • 22 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Sep 2009 Actual end date (August 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top